<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2283">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04390022</url>
  </required_header>
  <id_info>
    <org_study_id>SAINT</org_study_id>
    <nct_id>NCT04390022</nct_id>
  </id_info>
  <brief_title>Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial</brief_title>
  <acronym>SAINT</acronym>
  <official_title>Pilot Study to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinica Universidad de Navarra, Universidad de Navarra</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Barcelona Institute for Global Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Clinica Universidad de Navarra, Universidad de Navarra</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      SAINT is a double-blind, randomized controlled trial with two parallel groups that evaluates&#xD;
      the efficacy of ivermectin in reducing nasal viral carriage at seven days after treatment in&#xD;
      SARS-CoV-2 infected patients who are at low risk of progression to severe disease. The trial&#xD;
      is currently planned at a single center in Navarra.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SAINT is a double-blind, randomized controlled trial with two parallel groups that evaluates&#xD;
      the efficacy of ivermectin in reducing nasal viral carriage at seven days after treatment in&#xD;
      SARS-CoV-2 infected patients who are at low risk of progression to severe disease. The trial&#xD;
      is currently planned at a single center in Navarra.&#xD;
&#xD;
      Participants will be randomized to receive a single dose of 400 mcg/kg ivermectin or a&#xD;
      placebo. The randomization code will be generated by the trial statistician using blocks that&#xD;
      ensure balance between the groups.&#xD;
&#xD;
      The allocation will be made by the investigator after obtaining informed consent, and&#xD;
      confirmation of fulfillment of all inclusion and none of the exclusion criteria. The&#xD;
      investigational product will be administered by a researcher not involved in patient care or&#xD;
      participant follow up.&#xD;
&#xD;
      Participants will remain in the trial for a period of 28 days.&#xD;
&#xD;
      In the interests of public health and containing transmission of infection, trial visits will&#xD;
      be conducted in the participant's home by a clinical trial team comprising nursing and&#xD;
      medical members.&#xD;
&#xD;
      Subsequent visits will be to assess clinical and laboratory parameters.&#xD;
&#xD;
      A final study visit will be made for participants who withdraw prematurely from the study or&#xD;
      are withdrawn by the investigator.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 31, 2020</start_date>
  <completion_date type="Actual">October 9, 2020</completion_date>
  <primary_completion_date type="Actual">September 17, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>SAINT is a double-blind, randomized controlled trial with two parallel groups that evaluates the efficacy of ivermectin in reducing nasal viral carriage at seven days after treatment in SARS-CoV-2 infected patients who are at low risk of progression to severe disease.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Patients With a Positive SARS-CoV-2 PCR</measure>
    <time_frame>7 days post-treatment</time_frame>
    <description>Proportion of patients with a positive SARS-CoV-2 PCR from a nasopharyngeal swab at day 7 post-treatment. PCRs were performed using two target genes (E and N).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Viral Load</measure>
    <time_frame>Baseline and on days 4, 7, 14 and 21</time_frame>
    <description>Quantitative and semi-quantitative PCR in nasopharyngeal swab. PCRs were performed using two target genes (E and N).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fever and Cough Progression</measure>
    <time_frame>Days 4, 7, 14 and 21</time_frame>
    <description>Proportion of patients with fever and cough</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion at Day 21</measure>
    <time_frame>Up to and including day 21</time_frame>
    <description>Proportion of participants with positive IgG at day 21</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Drug-related Adverse Events</measure>
    <time_frame>7 days post treatment</time_frame>
    <description>Proportion of drug-related adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of IgG, IgM and IgA</measure>
    <time_frame>Up to and including day 28</time_frame>
    <description>Levels in median fluorescence intensity (MFI) of IgG, IgM and IgA against the receptor-binding domain of the spike glycoprotein of SARS-CoV-2 in plasma, measured by a Luminex assay.&#xD;
[Results not yet available]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Innate Immune Cells</measure>
    <time_frame>Up to and including day 7</time_frame>
    <description>Frequency (% over total PBMC) of innate immune cells (myeloid and plasmacytoid dendritic cells, NK cell, classical, intermediate and pro-inflammatory macrophages) measured in cryopreserved PBMC by flow cytometry.&#xD;
[Results not yet available]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency SARS-CoV-2-specific CD4+ T and and CD8+ T Cells</measure>
    <time_frame>Up to and including day 7</time_frame>
    <description>Frequency of CD4+ T and CD8+ T cells (% over total CD4+T and CD8+ T) expressing any functional marker upon in vitro stimulation of PBMC with SARS-CoV-2 peptides, measured by flow cytometry.&#xD;
[Results not yet available]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Results From Cytokine Human Magnetic 30-Plex Panel</measure>
    <time_frame>Up to and including day 28</time_frame>
    <description>Concentration (all in pg/mL) of epidermal growth factor (EGF), fibroblast growth factor (FGF), granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), tumour necrosis factor (TNF), interferon (IFN)-α, IFN-γ, interleukin (IL)-1RA, IL-1β, IL-2, IL-2R, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12(p40/p70), IL-13, IL-15, IL-17, IFN-γ induced protein (IP-10), monocyte chemoattractant protein (MCP-1), monokine induced by IFN-γ (MIG), macrophage inflammatory protein (MIP)-1α, MIP-1β in plasma measured by a Luminex assay using a commercially available kit (Cytokine Human Magnetic 30-Plex Panel from ThermoFisher).&#xD;
[Results not yet available]</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Covid-19</condition>
  <condition>Coronavirus Infection</condition>
  <condition>SARS-CoV-2 Infection</condition>
  <arm_group>
    <arm_group_label>Ivermectin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants on this arm will receive a single, oral dose of ivermectin 400 mcg/kg at the enrolment visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants on the arm will receive a single, oral dose of placebo tablets at the enrollment visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin</intervention_name>
    <description>Single dose of STROMECTOL® tablets at 400mcg/kg</description>
    <arm_group_label>Ivermectin</arm_group_label>
    <other_name>Stromectol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets will not match ivermectin but they will be administered by staff not involved in the clinical care.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients diagnosed with COVID-19 in the emergency room of the Clínica Universidad de&#xD;
             Navarra with a positive SARS-CoV-2 PCR.&#xD;
&#xD;
          2. Residents of the Pamplona basin (&quot;Cuenca de Pamplona&quot;)&#xD;
&#xD;
          3. The patient should be aged 18 to 59 years&#xD;
&#xD;
          4. Negative pregnancy test for women of child bearing age*&#xD;
&#xD;
          5. The patient or his/her representative, have given consent to participate in the study.&#xD;
&#xD;
          6. The patient should, in the investigator's opinion, be able to comply with all the&#xD;
             requirements of the clinical trial (including home follow up during isolation)&#xD;
&#xD;
               -  Women of child bearing age may participate if they use a safe contraceptive&#xD;
                  method for the entire period of the study and at least one month afterwards. A&#xD;
                  woman is considered to not have childbearing capacity if she is post-menopausal&#xD;
                  (minimum of 2 years without menstruation) or has undergone surgical sterilization&#xD;
                  (at least one month before the study)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known history of Ivermectin allergy&#xD;
&#xD;
          2. Hypersensitivity to any component of Stromectol®&#xD;
&#xD;
          3. COVID-19 Pneumonia&#xD;
&#xD;
               -  Diagnosed by the attending physician&#xD;
&#xD;
               -  Identified in a chest X-ray&#xD;
&#xD;
          4. Fever or cough present for more than 48 hours&#xD;
&#xD;
          5. Positive IgG against SARS-CoV-2 by rapid test&#xD;
&#xD;
          6. Age under 18 or over 60 years&#xD;
&#xD;
          7. The following co-morbidities (or any other disease that might interfere with the study&#xD;
             in the eyes of the investigator):&#xD;
&#xD;
               -  Immunosuppression&#xD;
&#xD;
               -  Chronic Obstructive Pulmonary Disease&#xD;
&#xD;
               -  Diabetes&#xD;
&#xD;
               -  Hypertension&#xD;
&#xD;
               -  Obesity&#xD;
&#xD;
               -  Acute or chronic renal failure&#xD;
&#xD;
               -  History of coronary disease&#xD;
&#xD;
               -  History of cerebrovascular disease&#xD;
&#xD;
               -  Current neoplasm&#xD;
&#xD;
          8. Recent travel history to countries that are endemic for Loa loa (Angola, Cameroon,&#xD;
             Central African Republic, Chad, Democratic Republic of Congo, Ethiopia, Equatorial,&#xD;
             Guinea, Gabon, Republic of Congo, Nigeria and Sudan)&#xD;
&#xD;
          9. Current use of CYP 3A4 or P-gp inhibitor drugs such as quinidine, amiodarone,&#xD;
             diltiazem, spironolactone, verapamil, clarithromycin, erythromycin, itraconazole,&#xD;
             ketoconazole, cyclosporine, tacrolimus, indinavir, ritonavir or cobicistat. Use of&#xD;
             critical CYP3A4 substrate drugs such as warfarin.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos J Chaccour, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinica Universidad de Navarra and Barcelona Institute of Global Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31108</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>May 7, 2020</study_first_submitted>
  <study_first_submitted_qc>May 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2020</study_first_posted>
  <results_first_submitted>December 9, 2020</results_first_submitted>
  <results_first_submitted_qc>December 10, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 17, 2020</results_first_posted>
  <last_update_submitted>December 10, 2020</last_update_submitted>
  <last_update_submitted_qc>December 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ivermectin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivermectin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 5, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/22/NCT04390022/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 12, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/22/NCT04390022/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ivermectin</title>
          <description>Participants on this arm received a single, oral dose of ivermectin 400 mcg/kg at the enrolment visit.&#xD;
(Single dose of STROMECTOL® tablets at 400mcg/kg)</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants on this arm received a single, oral dose of placebo tablets at the enrollment visit.&#xD;
(Placebo tablets did not match ivermectin but they were administered by staff not involved in the clinical care)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ivermectin</title>
          <description>Participants on this arm received a single, oral dose of ivermectin 400 mcg/kg at the enrolment visit.&#xD;
(Single dose of STROMECTOL® tablets at 400mcg/kg)</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants on this arm received a single, oral dose of placebo tablets at the enrollment visit.&#xD;
(Placebo tablets did not match ivermectin but they were administered by staff not involved in the clinical care)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26" lower_limit="19" upper_limit="36"/>
                    <measurement group_id="B2" value="26" lower_limit="21" upper_limit="44"/>
                    <measurement group_id="B3" value="26" lower_limit="20" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.5" lower_limit="19.6" upper_limit="27.8"/>
                    <measurement group_id="B2" value="22.9" lower_limit="21.0" upper_limit="24.8"/>
                    <measurement group_id="B3" value="22.9" lower_limit="20.6" upper_limit="26.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Any symptoms</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Earliest start of any symptom</title>
          <description>Presence of symptoms as well as their onset date was self-reported by each patient in the baseline visit.</description>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24" lower_limit="24" upper_limit="48"/>
                    <measurement group_id="B2" value="48" lower_limit="36" upper_limit="48"/>
                    <measurement group_id="B3" value="48" lower_limit="24" upper_limit="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fever</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Earliest start of fever</title>
          <description>Presence of fever as well as its onset date was self-reported by each patient in the baseline visit.</description>
          <population>Only patients with reported fever</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24" lower_limit="12" upper_limit="24"/>
                    <measurement group_id="B2" value="24" lower_limit="24" upper_limit="48"/>
                    <measurement group_id="B3" value="24" lower_limit="15" upper_limit="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cough</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Earliest start of cough</title>
          <description>Presence of cough as well as its onset date was self-reported by each patient in the baseline visit.</description>
          <population>Only patients with cough.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                    <count group_id="B2" value="2"/>
                    <count group_id="B3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24" lower_limit="16" upper_limit="36"/>
                    <measurement group_id="B2" value="10" lower_limit="8" upper_limit="12"/>
                    <measurement group_id="B3" value="18" lower_limit="8" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CRP</title>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.3" lower_limit="0.2" upper_limit="0.8"/>
                    <measurement group_id="B2" value="0.3" lower_limit="0.2" upper_limit="0.6"/>
                    <measurement group_id="B3" value="0.3" lower_limit="0.2" upper_limit="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ferritin</title>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="165.0" lower_limit="95.8" upper_limit="241.3"/>
                    <measurement group_id="B2" value="156.1" lower_limit="103.1" upper_limit="223.0"/>
                    <measurement group_id="B3" value="160.9" lower_limit="101.8" upper_limit="223.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>IL-6</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.5" lower_limit="5.1" upper_limit="9.6"/>
                    <measurement group_id="B2" value="4.5" lower_limit="3.0" upper_limit="6.5"/>
                    <measurement group_id="B3" value="5.3" lower_limit="3.8" upper_limit="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>D-Dimer</title>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="295" lower_limit="270" upper_limit="420"/>
                    <measurement group_id="B2" value="280" lower_limit="270" upper_limit="315"/>
                    <measurement group_id="B3" value="285" lower_limit="270" upper_limit="365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Patients With a Positive SARS-CoV-2 PCR</title>
        <description>Proportion of patients with a positive SARS-CoV-2 PCR from a nasopharyngeal swab at day 7 post-treatment. PCRs were performed using two target genes (E and N).</description>
        <time_frame>7 days post-treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ivermectin</title>
            <description>Participants on this arm received a single, oral dose of ivermectin 400 mcg/kg at the enrolment visit.&#xD;
(Single dose of STROMECTOL® tablets at 400mcg/kg)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants on this arm received a single, oral dose of placebo tablets at the enrollment visit.&#xD;
(Placebo tablets did not match ivermectin but they were administered by staff not involved in the clinical care)</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With a Positive SARS-CoV-2 PCR</title>
          <description>Proportion of patients with a positive SARS-CoV-2 PCR from a nasopharyngeal swab at day 7 post-treatment. PCRs were performed using two target genes (E and N).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PCR positivity (gene N)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCR positivity (gene E)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Viral Load</title>
        <description>Quantitative and semi-quantitative PCR in nasopharyngeal swab. PCRs were performed using two target genes (E and N).</description>
        <time_frame>Baseline and on days 4, 7, 14 and 21</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ivermectin</title>
            <description>Participants on this arm received a single, oral dose of ivermectin 400 mcg/kg at the enrolment visit.&#xD;
(Single dose of STROMECTOL® tablets at 400mcg/kg)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants on this arm received a single, oral dose of placebo tablets at the enrollment visit.&#xD;
(Placebo tablets did not match ivermectin but they were administered by staff not involved in the clinical care)</description>
          </group>
        </group_list>
        <measure>
          <title>Median Viral Load</title>
          <description>Quantitative and semi-quantitative PCR in nasopharyngeal swab. PCRs were performed using two target genes (E and N).</description>
          <units>copies/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Gene E - day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16850000" lower_limit="5915000" upper_limit="385250000"/>
                    <measurement group_id="O2" value="26700000" lower_limit="8325000" upper_limit="423500000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gene E - day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161000" lower_limit="2820" upper_limit="878000"/>
                    <measurement group_id="O2" value="493500" lower_limit="103700" upper_limit="9910000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gene E - day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1018" lower_limit="92" upper_limit="15445"/>
                    <measurement group_id="O2" value="23550" lower_limit="709" upper_limit="226500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gene E - day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="0" upper_limit="42"/>
                    <measurement group_id="O2" value="30" lower_limit="1" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gene E - day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gene N - day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="367000000" lower_limit="18350000" upper_limit="9280000000"/>
                    <measurement group_id="O2" value="327500000" lower_limit="58300000" upper_limit="6740000000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gene N - day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="269000" lower_limit="1885" upper_limit="1046500"/>
                    <measurement group_id="O2" value="2194500" lower_limit="73150" upper_limit="37100000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gene N - day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2255" lower_limit="938" upper_limit="34650"/>
                    <measurement group_id="O2" value="36800" lower_limit="4510" upper_limit="630500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gene N - day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86" lower_limit="0" upper_limit="1235"/>
                    <measurement group_id="O2" value="75" lower_limit="24" upper_limit="710"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gene N - day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="67"/>
                    <measurement group_id="O2" value="107" lower_limit="0" upper_limit="183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fever and Cough Progression</title>
        <description>Proportion of patients with fever and cough</description>
        <time_frame>Days 4, 7, 14 and 21</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ivermectin</title>
            <description>Participants on this arm received a single, oral dose of ivermectin 400 mcg/kg at the enrolment visit.&#xD;
(Single dose of STROMECTOL® tablets at 400mcg/kg)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants on this arm received a single, oral dose of placebo tablets at the enrollment visit.&#xD;
(Placebo tablets did not match ivermectin but they were administered by staff not involved in the clinical care)</description>
          </group>
        </group_list>
        <measure>
          <title>Fever and Cough Progression</title>
          <description>Proportion of patients with fever and cough</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever - Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever - Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever - Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever - Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough - Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough - Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough - Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough - Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion at Day 21</title>
        <description>Proportion of participants with positive IgG at day 21</description>
        <time_frame>Up to and including day 21</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ivermectin</title>
            <description>Participants on this arm received a single, oral dose of ivermectin 400 mcg/kg at the enrolment visit.&#xD;
(Single dose of STROMECTOL® tablets at 400mcg/kg)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants on this arm received a single, oral dose of placebo tablets at the enrollment visit.&#xD;
(Placebo tablets did not match ivermectin but they were administered by staff not involved in the clinical care)</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion at Day 21</title>
          <description>Proportion of participants with positive IgG at day 21</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Drug-related Adverse Events</title>
        <description>Proportion of drug-related adverse events</description>
        <time_frame>7 days post treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ivermectin</title>
            <description>Participants on this arm received a single, oral dose of ivermectin 400 mcg/kg at the enrolment visit.&#xD;
(Single dose of STROMECTOL® tablets at 400mcg/kg)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants on this arm received a single, oral dose of placebo tablets at the enrollment visit.&#xD;
(Placebo tablets did not match ivermectin but they were administered by staff not involved in the clinical care)</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Drug-related Adverse Events</title>
          <description>Proportion of drug-related adverse events</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Levels of IgG, IgM and IgA</title>
        <description>Levels in median fluorescence intensity (MFI) of IgG, IgM and IgA against the receptor-binding domain of the spike glycoprotein of SARS-CoV-2 in plasma, measured by a Luminex assay.&#xD;
[Results not yet available]</description>
        <time_frame>Up to and including day 28</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Innate Immune Cells</title>
        <description>Frequency (% over total PBMC) of innate immune cells (myeloid and plasmacytoid dendritic cells, NK cell, classical, intermediate and pro-inflammatory macrophages) measured in cryopreserved PBMC by flow cytometry.&#xD;
[Results not yet available]</description>
        <time_frame>Up to and including day 7</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency SARS-CoV-2-specific CD4+ T and and CD8+ T Cells</title>
        <description>Frequency of CD4+ T and CD8+ T cells (% over total CD4+T and CD8+ T) expressing any functional marker upon in vitro stimulation of PBMC with SARS-CoV-2 peptides, measured by flow cytometry.&#xD;
[Results not yet available]</description>
        <time_frame>Up to and including day 7</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Results From Cytokine Human Magnetic 30-Plex Panel</title>
        <description>Concentration (all in pg/mL) of epidermal growth factor (EGF), fibroblast growth factor (FGF), granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), tumour necrosis factor (TNF), interferon (IFN)-α, IFN-γ, interleukin (IL)-1RA, IL-1β, IL-2, IL-2R, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12(p40/p70), IL-13, IL-15, IL-17, IFN-γ induced protein (IP-10), monocyte chemoattractant protein (MCP-1), monokine induced by IFN-γ (MIG), macrophage inflammatory protein (MIP)-1α, MIP-1β in plasma measured by a Luminex assay using a commercially available kit (Cytokine Human Magnetic 30-Plex Panel from ThermoFisher).&#xD;
[Results not yet available]</description>
        <time_frame>Up to and including day 28</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>28 days</time_frame>
      <desc>Adverse events were assessed at each study visit (days 1, 4, 7, 14, 21 and 28)</desc>
      <group_list>
        <group group_id="E1">
          <title>Ivermectin</title>
          <description>Participants on this arm received a single, oral dose of ivermectin 400 mcg/kg at the enrolment visit.&#xD;
(Single dose of STROMECTOL® tablets at 400mcg/kg)</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants on this arm received a single, oral dose of placebo tablets at the enrollment visit.&#xD;
(Placebo tablets did not match ivermectin but they were administered by staff not involved in the clinical care)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Ferritin elevation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypochromic Microcytic Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>D-Dimer increase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dorsal discomfort of a mechanical nature</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Cold Sore</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute pharyngitis (tonsillitis)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Abdominal bacterial translocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening of acne</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Grade II burn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Carlos Chaccour</name_or_title>
      <organization>Barcelona Institute for Global Health</organization>
      <phone>0034666293112</phone>
      <email>carlos.chaccour@isglobal.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

